Germany’s Merck KGaA announced a cash offer to acquire U.S. lab‑tools maker Bio‑Techne. The transaction values the Minneapolis company at $11.4 billion, reflecting an enterprise value of roughly the same amount, and sets the purchase price at $73 per share. A 24% premium over Bio‑Techne’s prior close underscores Merck’s readiness to pay top‑dollar for niche life‑science assets.

The deal represents the first major move by newly appointed chief executive Kai Beckmann, who entered the role after a leadership shuffle aimed at reviving growth. Merck has struggled to expand its life‑science division organically, prompting the search for bolt‑on targets. Adding Bio‑Techne’s protein‑expression platforms and diagnostic kits should broaden the group’s product breadth and address market demand for integrated research solutions.

By securing Bio‑Techne, Merck positions itself against larger competitors such as Thermo Fisher Scientific and Danaher, which have pursued aggressive M&A strategies to dominate the reagents market. The acquisition expands Merck’s footprint in the high‑growth segments of cell‑culture media and molecular diagnostics, potentially shifting market share dynamics and prompting rival firms to reassess their own pipeline of deals.

Analysts will gauge whether the $11.4 billion price tag justifies the projected earnings uplift, which Merck expects to materialise within three years. The cash‑only structure raises the company's leverage, yet the scale of the transaction could unlock cross‑selling opportunities across its chemicals and life‑science units. EU antitrust approval remains the final hurdle before the deal closes.